Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03392389 · ClinicalTrials.gov registry record · Phase 1
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT03392389 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 124 participants.
The verdict
NCT03392389, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1653
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2019-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03392389
The ClinicalTrials.gov registry entry for NCT03392389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03392389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03392389 about?
NCT03392389 is a clinical study titled "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults". This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
What is the current status of trial NCT03392389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2017-12-04. Estimated completion is 2019-07-29.
What interventions are being tested in trial NCT03392389?
The interventions under investigation include: Placebo (OTHER), mRNA-1653 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03392389?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.